Abstract
Cefpirome, a fourth generation cephalosporin, was administered during 154 episodes of febrile neutropenia in 106 patients. We assessed the clinical efficacy of cefpirome and its activity against isolated pathogens in neutropenic patients with hematologic malignancies. In addition, the pharmacokinetics and optimal dosing regimen of cefpirome during neutropenia were investigated.
Vol. 90 No. 7 (2005): July, 2005 : Clinical Trial
Published By
Ferrata Storti Foundation, Pavia, Italy
